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In the recent years the aim of drug therapy in depres-
sion was redefined and specified. According to this, the
main goal of antidepressant treatment goes beyond
achieving some degree of response, or full response in
the sense of 50% reduction of a depression score, but to
remission in the global sense as well as on a more dif-
ferentiated level, which means almost complete relief of
depressive symptoms or at least almost complete relief
of the core or most relevant symptoms of depression.
This redefinition of the major therapeutic goal of antide-
pressive treatment was necessary, because several long-
term studies demonstrated, that only remission and in
this context the relief of the core or most relevant
symptoms of depression can guarantee with a reason-
ably high probability a positive outcome under long-
term aspects. The presentation will focus especially on
the issue of relief of the core or the most relevant symp-
toms of depression and the respective efficacy of drug
treatment with the recently licensed antidepressant ago-
melatine. Traditionally, especially depressed mood and
lack of interest were seen as the core symptoms of
depression. This is also mirrored in the current diagnos-
tic manuals. However, considering the frequency and
clinical relevance of sleep disturbances, and interpreting
this in the context of the aetiopathogenetic hypothesis
of disturbed circadian rhythm, sleep disorders can
be interpreted as a core symptom in another sense.
The same might be true for anxious symptoms, given
the high neurogenetic association of depressive and
anxious symptoms.
Agomelatine has demonstrated powerful antidepres-
sive efficacy, amongst others in terms of improvement
of depressive mood and in terms of remission. Accord-
ing to its neurobiological mood of action, agomelatine
has a special efficacy focus on disturbances of circadian
rhythms and demonstrates clinical efficacy in this
respect. Given the high frequency of anxious symptoms
in depression and the comorbidity between depression
and anxiety disorder, the efficacy of agomelatine in
anxious symptoms also seems to be a beneficial aspect
of the efficacy profile.
Taken together, these findings show that agomelatine
qualifies as an efficient option in the treatment of
depression based on its broad efficacy on the full spec-
trum of depressive symptoms, including those occurring
early as well as those that tend to persist late over the
course of the disorder.
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